{
  "timestamp": "2025-04-19 14:51:33",
  "phase": "Evolution",
  "round": 2,
  "elo_score": null,
  "content": "Chemotherapeutic agents inducing DSBs can paradoxically promote secondary neoplasms in survivors by causing mutations in non-target cells, and mutational signature analysis post-therapy can predict secondary cancer risk.  \n*Supporting evidence:* Secondary malignancies arise after DNA-damaging therapies [Morton 2014]. Therapy-induced mutational signatures are detectable in secondary cancers [Pich 2019, Nat Genet].\n\n---"
}